menu
    • menu

    Company profile for Ethypharm

    NEW Drugs in Dev: 4
    Ethypharm-PSE
    News
    Ethypharm Iberia adds Nefopam to its portfolio

    13 May 2025

    // PRESS RELEASE

    Recivit® returns to Ethypharm’s portfolio in France

    06 May 2025

    // PRESS RELEASE

    MDI Licenses Penthrox Distribution to Ethypharm in France

    29 Apr 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Ethypharm

    Contact Supplier

    Website

    DCAT Week

    The Fifty Sonesta New York

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.pharmacompass.com/video-supplier-spotlight/ethypharm/corporate-video

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Related CompaniesRelated Companies

    About

    Ethypharm is a European pharmaceutical company focused on CNS & Hospital injectables either through direct sales or through D&L.
    Ethypharm is also offering CDMO services from formulation, clinical to scale up & commercial phases.
    Ethypharm is your CDMO partner for sterile forms (Ampoule, Pre Filled syringes PFS, Vials, Lyo) & conventional (complex solid dosage forms & oral liquids), using conventional API & High potent, Narcotics, Controlled drugs.
    Our expertise in Flashtab, Tmask, Nanosizing, Multicaps, Transmucosal, & Orodispersible technologies, pellets, modified released forms enables us to develop innovative formulations.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EthypharmFrance Flag
    Country
    Country
    France
    Address
    Address
    194 Bureaux de la Colline, Batiment D – 12eme etage, 92213 Saint-Cloud Cedex
    Telephone
    Telephone
    +33 0141121720
    Client Email
    Email
    cheval.isabelle@ethypharm.com
    Client Website
    Website
    https://www.ethypharm.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ethypharm
    youtube
    YouTube
    https://www.youtube.com/@ethypharmsas6596
    Twitter
    Twitter
    https://x.com/ethypharm
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    dcat-week-png-51097.png

    DCAT Week

    The Fifty Sonesta New York

    envelop Contact Supplier

    DCAT Week

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-52691.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-71464.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2022

    read-more

      https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-79362.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pharmaceutical Capabilities

    read-more

      https://www.pharmacompass.com/pdf/party/content/ethypharm-party-content-84782.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Ethypharm Iberia adds Nefopam to its portfolio
    Ethypharm Iberia adds Nefopam to its portfolio

    13 May 2025

    // PRESS RELEASE

    https://www.ethypharm.com/blog/newsroom/ethypharm-iberia-adds-nefopam-to-its-portfolio/

    PRESS RELEASE
    13 May 2025
    Share Share
    Recivit® returns to Ethypharm’s portfolio in France
    Recivit® returns to Ethypharm’s portfolio in France

    06 May 2025

    // PRESS RELEASE

    https://www.ethypharm.com/blog/newsroom/recivit-returns-to-ethypharms-portfolio-in-france/

    PRESS RELEASE
    06 May 2025
    Share Share
    MDI Licenses Penthrox Distribution to Ethypharm in France
    MDI Licenses Penthrox Distribution to Ethypharm in France

    29 Apr 2025

    // PRESS RELEASE

    https://www.ethypharm.com/blog/newsroom/medical-developments-international-enters-licensing-agreement-for-penthrox-methoxyflurane-distribution-with-ethypharm-in-france/

    PRESS RELEASE
    29 Apr 2025
    Share Share
    Ethypharm Annonunces Appoints Éric Chevalier as HR Director
    Ethypharm Annonunces Appoints Éric Chevalier as HR Director

    04 Oct 2024

    // PRESS RELEASE

    https://www.ethypharm.com/blog/newsroom/ethypharm-announces-the-appointment-of-eric-chevalier-as-group-human-resources-director/

    PRESS RELEASE
    04 Oct 2024
    Share Share
    Acquisition Of Argatroban Business In Europe
    Acquisition Of Argatroban Business In Europe

    17 Jun 2024

    // PRESS RELEASE

    https://www.ethypharm.com/wp-content/uploads/2024/06/18-06-24-Press-Release-Argatroban-Ethypharm-Final.pdf

    PRESS RELEASE
    17 Jun 2024
    Share Share
    Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
    Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

    13 Jun 2024

    // PRESS RELEASE

    https://www.ethypharm.com/wp-content/uploads/2024/06/13062024_Group-PR_-Ethypharm-Expands-its-Mesalazine-Portfolio-in-China_FINAL-PR-NEWSWIRE.pdf

    PRESS RELEASE
    13 Jun 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Ethypharm Iberia Adds NEFOPAM to Portfolio

    Details:

    The deal aims to advance Nefopam HCl, a miscellaneous product, targeting dopamine/serotonin/norepinephrine reuptake.


    Lead Product(s): Nefopam Hydrochloride

    Therapeutic Area: Neurology Brand Name: Panagesic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: MEDOCHEMIE LTD

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement May 13, 2025

    Ethypharm

    01

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Nefopam Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : MEDOCHEMIE LTD

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Ethypharm Iberia Adds NEFOPAM to Portfolio

    Details : The deal aims to advance Nefopam HCl, a miscellaneous product, targeting dopamine/serotonin/norepinephrine reuptake.

    Product Name : Panagesic

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 13, 2025

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Recivit® Rejoins Ethypharm’s Portfolio in France

    Details:

    The deal aims to advance research on Fentanyl, a controlled substance targeting the Mu opioid receptor.


    Lead Product(s): Fentanyl

    Therapeutic Area: Neurology Brand Name: Recivit

    Study Phase: Approved FDFProduct Type: Controlled Substance

    Recipient: Grunenthal

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Termination May 06, 2025

    Ethypharm

    02

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Fentanyl

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Grunenthal

    Deal Size : Undisclosed

    Deal Type : Termination

    DEALS_DEV arrow-down

    Recivit® Rejoins Ethypharm’s Portfolio in France

    Details : The deal aims to advance research on Fentanyl, a controlled substance targeting the Mu opioid receptor.

    Product Name : Recivit

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    May 06, 2025

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Medical Developments Intl. Licenses Penthrox® to Ethypharm for Distribution in France

    Details:

    Through the licensing deal for Methoxyflurane, targeting GABA-A and Glycine receptors, the agreement aims to advance acute pain management.


    Lead Product(s): Methoxyflurane

    Therapeutic Area: Neurology Brand Name: Penthrox

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Medical Developments International

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 29, 2025

    Ethypharm

    03

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Methoxyflurane

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Medical Developments International

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Medical Developments Intl. Licenses Penthrox® to Ethypharm for Distribution in France

    Details : Through the licensing deal for Methoxyflurane, targeting GABA-A and Glycine receptors, the agreement aims to advance acute pain management.

    Product Name : Penthrox

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    April 29, 2025

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Acquisition of Argatroban Business in Europe

    Details:

    Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.


    Lead Product(s): Argatroban Monohydrate

    Therapeutic Area: Hematology Brand Name: Arganova

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Mitsubishi Tanabe Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition June 17, 2024

    Ethypharm

    04

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Argatroban Monohydrate

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Recipient : Mitsubishi Tanabe Pharma

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Acquisition of Argatroban Business in Europe

    Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.

    Product Name : Arganova

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    June 17, 2024

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

    Details:

    The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.


    Lead Product(s): Mesalazine

    Therapeutic Area: Immunology Brand Name: Etiasa

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Anbison

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition June 13, 2024

    Ethypharm

    05

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Anbison

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

    Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.

    Product Name : Etiasa

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    June 13, 2024

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Ethypharm Gains EU Approval for Morphine Immediate Release Tablets

    Details:

    Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.


    Lead Product(s): Morphine Sulfate

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Controlled Substance

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 02, 2021

    Ethypharm

    06

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Morphine Sulfate

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Ethypharm Gains EU Approval for Morphine Immediate Release Tablets

    Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    December 02, 2021

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine

    Details:

    Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by Dr Reddy's.


    Lead Product(s): Celecoxib

    Therapeutic Area: Neurology Brand Name: Elyxyb

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Dr. Reddy\'s Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition May 19, 2021

    Ethypharm

    07

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Celecoxib

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Dr. Reddy\'s Laboratories

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine

    Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...

    Product Name : Elyxyb

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 19, 2021

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China

    Details:

    Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.


    Lead Product(s): Vigabatrin

    Therapeutic Area: Neurology Brand Name: Kigabeq

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Orphelia Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 19, 2021

    Ethypharm

    08

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Vigabatrin

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Orphelia Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China

    Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.

    Product Name : Kigabeq

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    January 19, 2021

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm

    Details:

    Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.


    Lead Product(s): Triamcinolone Acetonide

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Medexus Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 18, 2020

    Ethypharm

    09

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Triamcinolone Acetonide

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Medexus Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH...

    Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    December 18, 2020

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Ethypharm, CTRS Partner to Register Orphacol® in China

    Details:

    Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.


    Lead Product(s): Cholic Acid

    Therapeutic Area: Genetic Disease Brand Name: Orphacol

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Laboratoires CTRS

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement November 10, 2020

    Ethypharm

    10

    Ethypharm

    France
    arrow
    DCAT Week
    The Fifty Sonesta New York
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Lead Product(s) : Cholic Acid

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved FDF

    Recipient : Laboratoires CTRS

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Ethypharm, CTRS Partner to Register Orphacol® in China

    Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.

    Product Name : Orphacol

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    November 10, 2020

    Ethypharm

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Discover the service capabilities from this company

    Packaging

    Discover their expertise for : Packaging

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Ethypharm full-view
    Formulation Development Services of Capsules
    full-view
    Controlled Substances - Narcotic Drugs
    full-view
    Sterile Liquid
    full-view
    Formulation Development Services of Tablets
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search